by B2i | Mar 29, 2022 | Press Releases
New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of $690,000 under the White House’s American Rescue PlanNew license agreement with Phibro Animal Health to...
by B2i | Mar 15, 2022 | Press Releases
JUPITER, Fla., March 15, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
by B2i | Feb 10, 2022 | Press Releases
The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease.JUPITER, Fla., Feb. 10, 2022 — Dyadic...
by B2i | Feb 7, 2022 | Press Releases
JUPITER, Fla., Feb. 07, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform...
by B2i | Jan 20, 2022 | Press Releases
JUPITER, Fla., Jan. 20, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...